{"id":"W4404940529","doi":"10.1038/s41375-024-02487-1","title":"Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia","year":2024,"lang":"en","type":"erratum","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Obinutuzumab; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Internal medicine; Oncology; Leukemia; Cancer research; Immunology; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.000887621,0.001610818,0.003666135,0.001015098,0.0002512606,0.000198306,0.0009754588,0.001303312,0.0001874255],"category_scores_gemma":[0.0006560345,0.001046184,0.0003990524,0.003145299,0.0008495881,0.0002138735,0.0008959176,0.00370687,0.0001108092],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.7421426,"about_ca_system_score_gemma":0.3726676,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.05438285,"about_ca_topic_score_gemma":0.09010755,"domain_scores_codex":[0.991372,0.0004701888,0.001954196,0.002310425,0.002117331,0.001775804],"domain_scores_gemma":[0.9951473,0.001031625,0.0006356322,0.0024605,0.0002706538,0.0004543236],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5558157,0.00130931,0.01633999,0.01899885,0.01327422,0.01736483,0.05442529,0.06627371,0.0002308588,0.0002420544,0.2377292,0.01799596],"study_design_scores_gemma":[0.5294312,0.0139291,0.006600892,0.01762559,0.002873717,0.001461495,0.006473165,0.3915932,0.0002871417,0.00001255251,0.02782474,0.001887212],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9557499,0.003698437,0.000003852985,0.00004033262,0.01614318,0.007582554,0.00005584039,0.0002653046,0.01646065],"genre_scores_gemma":[0.8502829,0.001356774,0.00003126925,0.00003335866,0.001159571,0.0005317695,0.0002033624,0.0003488237,0.1460521],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3694749,"threshold_uncertainty_score":0.9999932,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03698168111577174,"score_gpt":0.313390055003235,"score_spread":0.2764083738874633,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}